Hvivo Share Discussion Threads

[letmepass] 14/7/2018 10:37

Looks like fool Applegarth is trying to get lower. Did the same with BPC

[letmepass] 14/7/2018 10:28

 hVIVO reports positive results from the Phase IIb field study of FLU-v (FLU-v 003) representing a significant advance in the management of influenza disease ·      Primary and secondary endpoints achieved - induction of long-lasting T and B cell immunological responses·      Reduction in influenza infection rates and severity and duration of symptoms observed·      Treatment with FLU-v was well tolerated with an adverse event profile consistent with earlier studies·      Based on the results of two Phase IIb trials and previous studies, FLU-v is now ready for Phase III development·      FLU-v product profile is a broad spectrum (A, B and Pandemic strains), stand-alone, single injection influenza vaccine providing long-lasting protection and significant reduction in influenza symptoms and their severity·      By overcoming a number of key issues with current annual influenza vaccines it has the potential to address a much larger patient population and therefore has future blockbuster sales potential Webcast and conference call for analysts at 1pm BST today - see details below London, UK, 18 June 2018: hVIVO plc (AIM: HVO), a pioneer of human disease models and an industry leading clinical development services business, today announces positive results from a second Phase IIb study of FLU-v, (Study 003, NCT02962908). FLU-v is being developed by Imutex Limited, hVIVO's 49% joint venture with the SEEK Group. Trevor Phillips, Executive Chairman of hVIVO, said: "We are pleased that a second Phase IIb study has reported positive results for FLU-v. It is our view that FLU-v is now positioned to enter Phase III, with clear disease and symptom-based endpoints identified. The market potential for a broad spectrum universal influenza vaccine is significant. Along with our joint venture partner SEEK, and with a differentiated data-package, we will endeavour to maximise the strategic options available to the Company from FLU-v while still focusing on our other revenue streams." Gregory Stoloff, Chief Executive Officer of SEEK, said: "The disease and symptom reduction seen with this "universal" influenza vaccine candidate is achieved by stimulating an immune response mediated through T&B-cells to internal conserved influenza proteins, in contrast to seasonal influenza vaccines that prevent infection through antibody protection against external variable proteins. FLU-v is a synthetic polypeptide vaccine which means that it is not reliant on traditional manufacturing techniques with inherent risks, in particular the potential of a miss-match of virus particularly relevant for a pandemic strain.  FLU-v is designed to protect against a broad range of influenza viral strains and this includes unexpected seasonal strains or a potentially devastating pandemic strain." Dr. P.H.P. Groeneveld, Principal Investigator for FLU-003 study, Isala Hospitals, The Netherlands, said: "The broad spectrum late stage-development FLU-v vaccine is a promising step in the battle against influenza. It has shown to induce very potent Th1 immune response to influenza  proteins that could reduce infections and severe symptoms." Webcast and conference call for analysts at 1pm BST todayTrevor Phillips, Executive Chairman, Tim Sharpington, Managing Director R&D joined by Greg Stoloff, Chief Executive Officer of SEEK Group, will host a live conference call and webcast for analysts at 1pm BST today, 18 June 2018, to discuss this announcement. Please visit hVIVO's website approximately 10 minutes before the conference call to download the presentation slides. The presentation and access to the live webcast will be on hVIVO's website at www.hvivo.com. An audio replay file will be made available shortly afterwards via hVIVO's website. Further details on Phase IIb field study of FLU-v (FLU-v 003)UNISEC consortium EU-fundedA randomised, double-blind, placebo-controlled, single-centre trial part of the EU-funded European Universal Influenza Vaccines Secured Consortium ("UNISEC") project, to assess the immunogenicity, safety and exploratory efficacy of two different formulations and dosing regimens of FLU-v vaccine administered in healthy adults. In this trial, 176 subjects (aged 18-60 years) were assigned to either placebo or treatment arms. ·      The primary endpoint was to assess the immunogenicity responses of different formulations and regimens versus placebo at 42 and 180 days post vaccination in healthy volunteerso  The primary endpoint of enhancing T-cell responses was met demonstrating a statistically significant enhancement of the number of responders positive for interferon gamma (IFNg)producing T-cells (p

[applegarthlse] 14/7/2018 09:03

Are you invested here? I think it's gonna go sub 20p otherwise why sell now if next results will be good? Doesn't make sense

[mister md] 14/7/2018 08:42

Think Griffiths just takes stakes in undervalued companies then sells on the rally. He’s done it on many shares, GCM etc Dont think it has anything to do with shorting.
Once sellers are done shares tend to rally.

[applegarthlse] 14/7/2018 06:28

Anyone thinking of investing here DONT after that short taken out ! SUB 20p on way and silence on here and LSE speaks volumes ! The rampers know the games up .........lol..

[applegarthlse] 13/7/2018 23:48

Not the first time shorters have gone after Neil Woodford? Read this article......Woodford slates Kerrisdale for shorting ProthenaFeature29 JAN 2018Neil Woodford hasn't held back in his criticism of the US hedge fund, Kerrisdale Capital, which recently moved to short one of his fund's top holdings, Prothena (PRTA.O).COMMENTWoodford Ingrid SmithIrish biotech company Prothena forms a relatively significant chunk of the Woodford Patient Capital Trust (WPCT).In November 2017 Kerrisdale published a less than positive 29-page report on Prothena, explaining why it had chosen to short the company's shares to inevitably profit from a fall in the share price, which saw a fall of nearly 28 per cent in Dollar terms on the Nasdaq.SPONSORED CONTENT Kubernetes on Windows – are we crazy?Kubernetes on Windows – are we crazy?By G-ResearchThe drop in Prothena's share price has cost it its top spot in the Patient Capital portfolio. From being the biggest holding at over 16 per cent of assets in October, it dropped to number two at 9.2 per cent by December, behind Oxford Nanopore, an unlisted university seeking to revolutionise DNA analysis.In its report, Kerrisdale argued that trials on Prothena's main drug under development – an antibody used to treat a rare disease called amyloidosis – is likely to fail and predicted Prothena will be 'the next big biotech blowup'.Woodford for his part said he is confident that Prothena, whose shares have rallied 20 per cent since the beginning of the New Year, will publish successful trial results in the second quarter, and forecasts there will be good news from other investments.'The next 6-12 months should see some important inflexion points, Woodford said. He added, "We are very confident about the portfolio", and said many companies in the Woodford Patient Capital Trust are "on the cusp" of a breakthrough.Some market watchers see Kerrisdale's comments as just another example of the long running feud between the hedge fund's founder, Sahm Adrangi, and Woodford.It was less than three years ago that Kerrisdale forecast shares in Allied Minds – a technology venture capitalist and another of the fund manager's long-term holdings – would tumble, describing many of its investments as 'duds'.Woodford has said Kerrisdale's raison d'etre is to frighten the market at a time when the market welcomes being frightened."It doesn't matter if what they said about Allied Minds and Prothena is totally inaccurate and unsubstantiated," Woodford told investors recently at a Winterflood Securities event in London.The star fund manager also argues that the financial press has a lot to answer for, by giving Kerrisdale "the oxygen of publicity" in order to achieve the self-fulfilled prophecy of a share price fall.The last year for Neil Woodford could be viewed as his very own annus horribilis, with all three of his funds having experienced a downturn in performance as key holdings have struggled – including the Woodford Equity Income fund which also invests in Prothena.And Woodford Patient Capital, which is an investment trust focused on early stage healthcare and technology companies, has certainly fared the worst.Since its inception in 2015 the fund's shares have fallen over 17 per cent to 83.4p, having lost 7 per cent of their value in 2017 and 9.75 per cent in 2016. This contrasts to August 2015, when they they were reported to show a 15 per cent premium over net asset value (NAV), but now trade at an 8.7 per cent discount to NAV.However, falls in the value of the underlying portfolio of 81 companies have been smaller, and the trust has still been able to report successes amongst it portfolio holdings – mostly notably from online estate agent Purplebricks(PURP), whose shares significantly jumped 194 per cent in 2017, according to Woodford Investment Management.

[applegarthlse] 13/7/2018 23:45

blinkx - well known investor Richard Griffiths further increases stake, but its still a sellBy Steve Moore | Friday 10 October 2014 Disclosure: I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from ShareProphets). I have no business relationship with any company whose stock is mentioned in this article.Internet media company blinkx plc (BLNX) has announced that Richard Griffiths (a former director of Evolution Group, which would progress to the FTSE-250, and well known smaller companies investor) has increased his interest in the company's shares to 4.62% of the issued share capital. This follows an increase to a 3.50% interest a few weeks before the earlier-this-month profit warning which saw the shares fall from more than 35p to briefly sub 30p. With them currently at 31.75p, is Griffiths' latest move a wiser one?The market cap is now £127 million and the last published balance sheet (as at 31st March 2014) showed cash (net) of $126.91 million (currently equating to approaching £79 million) and total assets (excluding goodwill and intangibles) of $187.29 million against total liabilities of $40.79 million.There thus looks to be some decent tangible underpinning for the valuation but this needs to be considered in the context of a significant decline in trading performance – the company reporting earlier this month that "considerably slowed" revenue trends "continued into the second quarter". As such, the company now expects to report "approximately break-even" adjusted EBITDA on revenue of $102 million-$104 million for the six months ended 30th September 2014.This is likely to have seen some of the tangible asset backing eroded and issues and a lack of forward visibility I noted in July largely look to remain, though the company emphasises that it "has seen sequential month-on-month growth since July, and management believes the company has reached an inflection point... We have taken decisive steps to fortify our business model and realign our resources to target growing areas of the sector, and we feel confident in our prospects going forward".More will become clearer with the company to "provide a more detailed update and outlook when it publishes its interim results on 11 November 2014" but I continue to currently consider the shares a speculation on the company's ability to deliver a sustainable cash generative recovery, rather than a solid, value investment. That is wholly unproven.Griffiths may well wish to average down but he can afford to add to his losses. Can you? This remains a sell.

[applegarthlse] 13/7/2018 23:16

One of the articles I've found.........LSE to examine bank chief's sale of Incite stakeBy Richard Fletcher12:01AM GMT 01 Feb 2004The London Stock Exchange is to examine why the sale of a £1.5m stake in Incite Holdings by Richard Griffiths, the chairman of the investment bank Evolution Beeson Gregory, was not disclosed for three months.Shares in Incite, a telecoms company which counts Lawrence Dallaglio, the newly appointed England rugby captain, as its market development director for sport, were suspended last Friday.Incite has admitted it is seeking additional working capital. Its urgent need for new money comes less than five months after it raised £1.5m from investors by listing on Aim.Griffiths sold his entire 8.2 per cent stake in the firm on October 14 2003 but the market was not informed until January 14. Stock Exchange rules require that shareholders who control a stake in excess of 3 per cent must notify companies "without delay" if they sell or buy shares. The company must then notify the market immediately."It was just an oversight, an administrative error," said Griffiths this weekend. "The delay was at the company's end, not my end. I told the company as soon as I sold the stake," he added later. Incite was unavailable for comment.Related Articles6 December 2003: Evolution faces a formal inquiry over short selling 01 Feb 20041 October 2003: Beeson Gregory seeks £25m with Aim float 01 Feb 200416 September 2003: Dallaglio wins place in Incite's top team 01 Feb 2004Incite has been a very profitable investment for Griffiths. According to its prospectus, he invested £218,666 for an 8.2 per cent stake just a week before the company announced plans to list.The value of that stake more than doubled three weeks later when the company listed and within a month it was worth over £1m. With the shares close to a record high on October 12 2003, Griffiths sold 2,392,718 shares at 67p, netting him a profit of £1.3m on his £218,666 investment.According to Griffiths, a number of his friends also invested in the company. "I wish I had never seen the thing. It has not been worth the hassle. Everyone keeps ringing me up asking what is going on," said Griffiths."I get them right and wrong like everyone else," he added.Shares in Incite have fallen by nearly 60 per cent since Griffiths sold his stake. With the future of the company uncertain, the shares were suspended on Friday at 27.5p. According to an executive at the London Stock Exchange, it is inevitable that it will now look at the delay in informing the market.Incite runs subscription services for sports fans, who receive pictures and news on their mobile phones.In its statement to the Stock Exchange on Friday, Incite claimed that it was in talks to acquire "substantial assets". This is understood to refer to talks with NTL that would see Incite acquire the rights to market telecom services to a number of football clubs.Beaumont Cornish is the nominated adviser to Incite. The company's stockbroker is Christows, a division of Evolution Beeson Gregory.

[applegarthlse] 13/7/2018 23:15

I've been doing my research on Richard Griffiths and controlled undertakings as named in today's RNS and it seems he's engaged in short selling if I've read what Google shows me? Very worrying and I believe that 400k sell today is a short taken out in the stock? What do they know that we don't? He must be confident this is going to tank? Don't believe me just google Richard Griffiths and controlled undertakings and see what it throws up

[letmepass] 13/7/2018 21:11

1.2 million sold today. Can't have many left.

[mister md] 13/7/2018 19:19

Some interesting big volume trades showing

[billthebank] 13/7/2018 18:14

Looks like Woidfird will be hoovering up all of his holding though so should be done by next week.Tbis share is a keeper.Patience ix all that is needed!!!

[discojames] 13/7/2018 18:11

What makes you think they are out of the way?

[stealive] 13/7/2018 17:52

Roll on Monday. Sells out of the way

[bauchsapt] 13/7/2018 15:50

Rns out griffiths below 3%. Wonder if Woodford been buying there shares too.

[discojames] 13/7/2018 14:16

Wow, so here we are in the 60s, not so 'desperate', now am I? It's funny to watch desperate holders talk down to people who just point out facts, only to watch it blow up in their faces

[bernymadoff] 13/7/2018 14:07

The phrase missing the wood for the trees springs to mind. Clearly IP are selling and Woodford is buying. Let's see where this is in a few months time

[discojames] 13/7/2018 14:00

Two sales over 100k Berny. Whats your feeling now?

[billthebank] 13/7/2018 13:49

Wow two chunky sales gone through today

[mister md] 13/7/2018 09:32

No idea if someone still offloading

[applegarthlse] 12/7/2018 21:55

Here and LSE board silent ? Seems like the paid rampers by the brokers clocked off at 18:00......lol... Ramping pigs!!!!!